Abstracts Archive - Page 1179 of 2425 - ACR Meeting Abstracts

Abstract Number: 2618 • 2018 ACR/ARHP Annual Meeting
Drug Survival of Non TNF Inhibitors Bdmards in Psoriatic Arthritis (Ustekinumab/Secukinumab) : A Real-Word Multicentric Cohort of 161 Patients
Jean-Guillaume Letarouilly¹, Jeremie Sellam², Pascal Richette³, Philippe Dieude⁴, Pascal Claudepierre⁵, Tristan Pascart⁶, Eric Houvenagel⁶, Marie-Hélène Guyot⁷, Nicolas Segaud⁸, Pascal Coquerelle⁹, Frederic Maury¹⁰, Laurent Marguerie¹¹, Xavier Deprez¹², Jean-Hugues Salmon¹³, Guy Baudens¹², Elisabeth Gervais¹⁴, Maeva Kyheng¹⁵, Julien Paccou¹ and René-Marc Flipo¹, ¹Rheumatology, Lille University Hospital, Lille, France, ²AP-HP Saint-Antoine hospital, Service de Rhumatologie, Inserm UMRS_938, Paris, France, ³Rheumatology, Université Paris Diderot, Paris, France, ⁴Université Paris-Diderot, Paris, France, ⁵Hôpital Henri Mondor, Créteil, France, ⁶Rheumatology, Groupe Hospitalier de l'Institut Catholique de Lille, Lomme, France, ⁷Internal medicine, Hospital of Roubaix, Roubaix, France, ⁸Internal medicine, Hospital of Armentieres, Armentières, France, ⁹rheumatology, Hospital of Bethune, Bethune, France, ¹⁰Rheumatology, Private Practice, Beuvry, France, ¹¹Rheumatology, Institut Calot, Berck, France, ¹²Rheumatology, CHR Valenciennes, Valenciennes, France, ¹³Service de Rhumatologie, CHU Reims, Hôpital Maison Blanche, Reims, France, ¹⁴Rhumatologie, University Hospital, Poitiers, France, ¹⁵Lille University Hospital, EA 2694 - Santé publique : épidémiologie et qualité des soins, F-59000, Lille, France
Background/Purpose: Ustekinumab and secukinumab are two new Biologic Disease-modifying Antirheumatic Drugs (bDMARDs) in severe psoriatic arthritis (PsA), targeting respectively IL12-23 and IL 17. Data in…
Abstract Number: 2619 • 2018 ACR/ARHP Annual Meeting
Effect of Statins on CRP Elevation in Patients with Psoriatic Arthritis
Lesley Jackson¹, Jeffry Bieber^1,2 and R. Eric Heidel³, ¹Graduate School of Medicine, Department of Internal Medicine, University of Tennessee Medical Center Knoxville, Knoxville, TN, ²UT Rheumatology, Knoxville, TN, ³Graduate School of Medicine, Division of Biostatistics, and Department of Surgery, University of Tennessee Medical Center Knoxville, Knoxville, TN
Background/Purpose: It is well established that psoriatic arthritis is associated with increased cardiovascular disease risk. The use of statins may impart anti-inflammatory effects, possibly through…
Abstract Number: 2620 • 2018 ACR/ARHP Annual Meeting
The Treatment Choices and Response for a Psoriatic Arthritis Inception Cohort
Umut Kalyoncu¹, Abdulsamet Erden¹, Gezmis Kimyon², Timucin Kasifoglu³, Atalay Dogru⁴, Ozun Bayndır⁵, Ediz Dalkiliç⁶, Cem Ozisler¹, Ayse Balkarli¹, Gozde Cetin⁷, Rıdvan Mercan⁸, Orhan Kucuksahin¹, Ahmet Omma¹, Serpil Ergullu Esmen⁹, Levent Kilic¹, Dilek Solmaz¹⁰, Muhammet Cinar¹, Seval Pehlevan¹¹, Sema Yilmaz⁹, Tuncay Duruoz¹¹, Sibel Bakirci⁵ and Sibel Zehra Aydın¹², ¹PsART study group, Ankara, Turkey, ²PsART study group, Hatay, Turkey, ³PsART study group, Eskişehir, Turkey, ⁴PsART study group, Isparta, Turkey, ⁵PsART study group, Izmir, Turkey, ⁶PsART study group, Bursa, Turkey, ⁷PsART study group, Kahramanmaras, Turkey, ⁸PsART study group, Tekirdag, Turkey, ⁹PsART study group, Konya, Turkey, ¹⁰PsART study group, Ottawa, OH, Canada, ¹¹PsART study group, Istanbul, Turkey, ¹²PsART study group, Ottawa, ON, Canada
Background/Purpose: There had been a lot of new therapeutic agents for the treatment of Psoriatic Arthritis (PsA) in the last decade. In this study we…
Abstract Number: 2621 • 2018 ACR/ARHP Annual Meeting
Predictors of Survival of Adalimumab Treatment in the Management of Ankylosing Spondylitis and Psoriatic Arthritis in Canadian Routine Care
Louis Bessette^1,2, Majed Khraishi³, Jacqueline Stewart^4,5, Andrew Chow^6,7, Viktoria Pavlova⁸, Brandusa Florica^6,9 and Valencia P. Remple^10,11, ¹Centre Hospitalier de l'Université Laval, Quebec, QC, Canada, ²Rheumatology, Laval University, Quebec, QC, Canada, ³Memorial University of Newfoundland, St. John's, NF, Canada, ⁴Penticton Regional Hospital, Penticton, BC, Canada, ⁵University of British Columbia, Penticton, BC, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Trillium Health Partners Credit Valley Hospital, Mississauga, ON, Canada, ⁸McMaster University, Hamilton, ON, Canada, ⁹Trillium Health Partners, Mississauga, ON, Canada, ¹⁰AbbVie Corporation, Montreal, QC, Canada, ¹¹School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Biologics therapy survival is often used as a proxy for treatment effectiveness and safety. However, it may be influenced by patient characteristics, utilization patterns,…
Abstract Number: 2622 • 2018 ACR/ARHP Annual Meeting
Regional and Temporal Variation in the Baseline Profile of Ankylosing Spondylitis Patients Initiating Adalimumab Following Failure of Non-Biologic Treatment in Canadian Routine Care
Louis Bessette^1,2, Majed Khraishi³, Viktoria Pavlova⁴, Brandusa Florica^5,6 and Valencia P. Remple^7,8, ¹Centre Hospitalier de l'Université Laval, Quebec, QC, Canada, ²Rheumatology, Laval University, Quebec, QC, Canada, ³Memorial University of Newfoundland, St. John's, NF, Canada, ⁴McMaster University, Hamilton, ON, Canada, ⁵Trillium Health Partners, Mississauga, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada, ⁸AbbVie Corporation, Montreal, QC, Canada
Background/Purpose: Treatment selection in Canadian routine clinical care is based on the judgment of the treating physician but is also affected by treatment guidelines and…
Abstract Number: 2623 • 2018 ACR/ARHP Annual Meeting
Efficacy of TNF Inhibitors and Predictive Factors of Clinical Presentation in Patients with Psoriatic Arthritis
Diego Benavent¹, Chamaida Plasencia¹, Victoria Navarro-Compán², Borja Hernández-Breijo³, Alejandro Villalba¹, Diana Peiteado⁴, Elisa Fernández¹, Patricia Bogas⁵, Mercedes de Diego¹ and Alejandro Balsa⁵, ¹Rheumatology, La Paz University Hospital, Madrid, Spain, ²Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, Madrid, Spain, ³Immunology, La Paz University Hospital, Madrid, Spain, ⁴Rheumatology, Rheumatology, La Paz University Hospital, Madrid, Spain, ⁵Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneus disease. Patients with PsA may have predominant axial (axPsA) or peripheral (pPsA) manifestations but the factors influencing on…
Abstract Number: 2624 • 2018 ACR/ARHP Annual Meeting
Cost-Effectiveness of Swapping Strategy for Established Psoriatic Arthritis and Immediate Versus Standard Swapping Strategy for Early Psoriatic Arthritis
Dongze Wu¹, Tingting Xu², Isaac T. Cheng¹, Steven H.M. Lam¹, Jiang Yue¹, Priscilla Wong¹, Edmund Li¹, Tena K. Li¹ and Lai-Shan Tam³, ¹Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, China, ²China Center for Health Development Studies, Peking University, Beijing, China; Department of Health Policy and Administration, Peking University School of Public Health, Beijing, China, Beijing, China, ³Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, Hong Kong
Background/Purpose: For patients with psoriatic arthritis (PsA) failing the first TNF-inhibitor, switching to biologic DMARDs [bDMARDs] with different mechanism of actions (swapping strategy) may be…
Abstract Number: 2625 • 2018 ACR/ARHP Annual Meeting
TNF Inhibitor Reduces ASDAS Faster and More Stable in Ankylosing Spondylitis Patients: Results from a Real World Prospective Cohort Managed By Smart Phone System
Xiaojian Ji, Jian Zhu, Jianglin Zhang and Feng Huang, Rheumatology, Chinese PLA General Hospital, Beijing, China
Background/Purpose: The Smart-phone Spondyloarthritis Management System (SpAMS) is a mobile health tool, specifically designed to conduct prospective clinical studies on SpA/AS in China, using real-world…
Abstract Number: 2626 • 2018 ACR/ARHP Annual Meeting
Normalization of CRP Levels and Clinical Response to Ixekizumab in Patients with Psoriatic Arthritis: Results from the Spirit Studies
Bernard Combe¹, Paul Emery², Annelies Boonen³, Soyi Liu Leage⁴, Christophe Sapin⁴, Natalia Bello⁵ and Maxime Dougados⁶, ¹CHU, Montpellier University, Montpelier, France, Montpellier, France, ²Leeds Musculoskeletal Biomedical Research Unit, LTHT Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, Leeds, United Kingdom, ³Division of Rheumatology, Maastricht University, School for Public Health and Primary Care, Maastricht University Medical Centre, The Netherlands, Maastricht, Netherlands, ⁴Lilly France, Neuilly sur Seine Cedex, France, Neuilly sur Seine Cedex, France, ⁵Eli Lilly and Company (Spain), Alcobendas, Spain, Alcobendas, Spain, ⁶Rheumatology Department, Cochin Hospital, AP-HP, Paris Descartes University, Paris, France, Paris, France
Background/Purpose: It is important to understand the association between early changes in inflammatory biomarkers and treatment response at later times after initiation of a biologic…
Abstract Number: 2627 • 2018 ACR/ARHP Annual Meeting
Not All Clinical Responders in SLE Are Equal: Comparison of Subcutaneous Belimumab + Standard of Care Responders to Placebo + Standard of Care Responders
William Stohl¹, Milena Kurtinecz², Joe Eastman³, Vanessa Castellano⁴, Chrysa Mahoney⁴, Tania Gonzalez-Rivera² and Bonnie Pobiner⁴, ¹Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ²GlaxoSmithKline, Philadelphia, PA, ³GlaxoSmithKline (at the time of the study), Research Triangle Park, NC, ⁴GlaxoSmithKline, Research Triangle Park, NC
Background/Purpose: To determine whether degree of response among responders to subcutaneous (SC) belimumab (BEL) + standard of care (SoC) is greater than that for responders…
Abstract Number: 2628 • 2018 ACR/ARHP Annual Meeting
Hydroxychloroquine and Prednisone Have Different Effects on Antiphospholipid Antibodies in SLE, with Hydroxychloroquine Not Reducing IgA Anticardiolipin
Michelle Petri¹, Mertcan Avci² and Laurence S Magder³, ¹Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ²Medicine, Istanbul Faculty of Medicine, Istanbul, Turkey, ³Epidemiology and Public Health, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Antiphospholipid antibodies in SLE may be changed by treatment, but past studies have been conflicting. We examined the impact of starting or stopping two…
Abstract Number: 2629 • 2018 ACR/ARHP Annual Meeting
Longitudinal Analysis of Persistent Positivity of Antiphospholipid Antibodies in Systemic Lupus Erythematosus
Michelle Petri¹, Mertcan Avci² and Laurence S Magder³, ¹Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ²Medicine, Istanbul Faculty of Medicine, Istanbul, Turkey, ³Epidemiology and Preventive Medicine, University of MD, Baltimore, MD
Background/Purpose: ‘Persistent positivity” has been a part of laboratory criteria for antiphospholipid syndrome classification criteria and requires two positive tests. We investigated the clinical utility…
Abstract Number: 2630 • 2018 ACR/ARHP Annual Meeting
Complement C4d Split Products in Combination with Lupus Anticoagulant and Low Complement Associate with Thrombosis in Systemic Lupus Erythematosus
Michelle Petri¹, John Conklin², Robert Apilado², Tyler O'Malley², JoAnne Ligayon², Leilani Wolover² and Thierry Dervieux², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Exagen Diagnostics, Inc., Vista, CA
Background/Purpose: Lupus anticoagulant (LAC) is an established risk factor for thrombosis in systemic Lupus erythematosus (SLE). Emerging data suggest that activation of the complement system…
Abstract Number: 2631 • 2018 ACR/ARHP Annual Meeting
Hydroxychloroquine Blood Levels Are Significantly Associated with Cardiovascular Risk Factors
Michelle Petri¹, Daniel Goldman¹ and Laurence S Magder², ¹Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ²Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: In studies of SLE patients, the benefits of hydroxychloroquine (HCQ) extend beyond control of disease activity. In particular, HCQ use has decreased multiple cardiovascular…
Abstract Number: 2632 • 2018 ACR/ARHP Annual Meeting
Rates and Predictors of Thirty-Day Readmission Among Patients Hospitalized for Systemic Lupus Erythematosus at a Single Tertiary Care Center
Stephen Mullis¹ and Dennis Ang², ¹Department of Internal Medicine, Section on Rheumatology and Immunology, Wake Forest School of Medicine, Winston Salem, NC, ²Wake Forest University School of Medicine, Winston-Salem, NC
Background/Purpose: Systemic lupus erythematosus (SLE) has a 27.2% all-cause 30 day readmission rate, the 6th highest principle diagnosis among all medical conditions. The primary objective…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].